comparemela.com

Latest Breaking News On - Revance therapeutics company profile - Page 1 : comparemela.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average […]

United-states
Piper-sandler
Tobin-schilke
Nasdaq
Needham-company
Principal-financial-group-inc
Goldman-sachs-group
Barclays
Securities-exchange-commission
Revance-therapeutics-inc
Vanguard-group-inc
Revance-therapeutics-company-profile

Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $11.50

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]

United-states
Los-angeles
California
Zurcher-kantonalbank-zurich-cantonalbank
Tobin-schilke
Piper-sandler
Securities-exchange-commission
Nasdaq
Revance-therapeutics-company-profile
Goldman-sachs-group
Barclays
Los-angeles-capital-management

Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8.00 at The Goldman Sachs Group

Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8.00 at The Goldman Sachs Group
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Piper-sandler
Dustins-sjuts
Tobin-schilke
Revance-therapeutics-company-profile
Barclays
Asset-management-inc
Needham-company
Securities-exchange-commission
Goldman-sachs-group
Invesco-ltd
Revance-therapeutics-inc

Needham & Company LLC Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $12.00

Needham & Company LLC Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $12.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Switzerland
United-states
Swiss
Tobin-schilke
Piper-sandler
Dustins-sjuts
Essex-investment-management-co
Swiss-national-bank
Revance-therapeutics-inc
Northrock-partners
Goldman-sachs-group
Securities-exchange-commission

Mizuho Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $8.00

Mizuho Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $8.00
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United-states
Switzerland
Swiss
Piper-sandler
Tobin-schilke
Securities-exchange-commission
Revance-therapeutics-company-profile
Blair-william-co
Needham-company
Goldman-sachs-group
Northrock-partners
Essex-investment-management-co

vimarsana © 2020. All Rights Reserved.